Literature DB >> 21640619

Focal positive prostate-specific membrane antigen (PSMA) expression in ganglionic tissues associated with prostate neurovascular bundle: implications for novel intraoperative PSMA-based fluorescent imaging techniques.

Alcides Chaux1, John Eifler, Sarah Karram, Turki Al-Hussain, Sheila Faraj, Martin Pomper, Ronald Rodriguez, George J Netto.   

Abstract

OBJECTIVE: Prostate specific membrane antigen (PSMA) is primarily expressed in glandular prostatic tissue and is frequently utilized to detect primary or metastatic prostatic adenocarcinoma (CaP). A purported novel application of PSMA detection is the intraoperative real-time identification of CaP using radioimmunoscintigraphy to define the extension of the surgical resection. Considering that PSMA expression has been reported in other tissues, we evaluated its immunoexpression in prostatic neurovascular bundle elements to assess the convenience and safety of the aforementioned procedure.
MATERIALS AND METHODS: Twenty consecutive specimens of radical prostatectomy (RP) were retrieved from our surgical pathology archives. PSMA immunoexpression (Clone 3E6, DAKO) was assessed in a representative section from each specimen containing neurovascular bundle elements.
RESULTS: PSMA expression was documented in 20/20 of examined CaP slides. Most cases exhibited an apical/cytoplasmic or cytoplasmic with membranous accentuation pattern of staining. Focal weak to moderate cytoplasmic staining was detected in associated ganglionic tissue in 3/15 of the examined RP. In all cases, staining was cytoplasmic, less extensive, and weaker than the pattern observed in CaP. None of the peripheral nerve sheath cells or lymphovascular components of the examined neurovascular bundles were positive for PSMA.
CONCLUSIONS: We found focal positive PSMA expression in the ganglionic cells of the prostatic neurovascular bundle. Our results suggest that the radioimmunoscintigraphic detection of radiolabeled PSMA antibodies might not be entirely specific for prostatic cells; this observation must be taken into account should an intraoperative PSMA-based fluorescent imaging technique be used to define the extension of the surgical procedure.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21640619      PMCID: PMC4074903          DOI: 10.1016/j.urolonc.2011.04.002

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  18 in total

1.  Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.

Authors:  S S Chang; V E Reuter; W D Heston; N H Bander; L S Grauer; P B Gaudin
Journal:  Cancer Res       Date:  1999-07-01       Impact factor: 12.701

2.  Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.

Authors:  Neil H Bander; Matthew I Milowsky; David M Nanus; Lale Kostakoglu; Shankar Vallabhajosula; Stanley J Goldsmith
Journal:  J Clin Oncol       Date:  2005-04-18       Impact factor: 44.544

Review 3.  Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience.

Authors:  M Han; A W Partin; C R Pound; J I Epstein; P C Walsh
Journal:  Urol Clin North Am       Date:  2001-08       Impact factor: 2.241

4.  Expression of prostate-specific membrane antigen in transitional cell carcinoma of the bladder: prognostic value?

Authors:  J L Gala; S Loric; Y Guiot; S R Denmeade; A Gady; F Brasseur; M Heusterspreute; P Eschwège; P De Nayer; P Van Cangh; B Tombal
Journal:  Clin Cancer Res       Date:  2000-10       Impact factor: 12.531

5.  Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer.

Authors:  Catherine A Foss; Ronnie C Mease; Hong Fan; Yuchuan Wang; Hayden T Ravert; Robert F Dannals; Rafal T Olszewski; Warren D Heston; Alan P Kozikowski; Martin G Pomper
Journal:  Clin Cancer Res       Date:  2005-06-01       Impact factor: 12.531

Review 6.  Technology insight: monoclonal antibody imaging of prostate cancer.

Authors:  Neil H Bander
Journal:  Nat Clin Pract Urol       Date:  2006-04

7.  A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer.

Authors:  Michael D Henry; Shenghua Wen; Matthew D Silva; Sudeep Chandra; Mark Milton; Peter J Worland
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

8.  Prostate-specific membrane antigen expression in normal and malignant human tissues.

Authors:  D A Silver; I Pellicer; W R Fair; W D Heston; C Cordon-Cardo
Journal:  Clin Cancer Res       Date:  1997-01       Impact factor: 12.531

9.  Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia.

Authors:  C Marchal; M Redondo; M Padilla; J Caballero; I Rodrigo; J García; J Quian; D G Boswick
Journal:  Histol Histopathol       Date:  2004-07       Impact factor: 2.303

10.  Expression of prostate-specific membrane antigen in normal and malignant human tissues.

Authors:  Yoshihisa Kinoshita; Katsuyuki Kuratsukuri; Steve Landas; Katsumi Imaida; Peter M Rovito; Ching Y Wang; Gabriel P Haas
Journal:  World J Surg       Date:  2006-04       Impact factor: 3.282

View more
  4 in total

1.  Prodrug strategy for PSMA-targeted delivery of TGX-221 to prostate cancer cells.

Authors:  Yunqi Zhao; Shaofeng Duan; Xing Zeng; Chunjing Liu; Neal M Davies; Benyi Li; M Laird Forrest
Journal:  Mol Pharm       Date:  2012-05-01       Impact factor: 4.939

2.  Visualization of prostatic nerves by polarization-sensitive optical coherence tomography.

Authors:  Yeoreum Yoon; Seung Hwan Jeon; Yong Hyun Park; Won Hyuk Jang; Ji Youl Lee; Ki Hean Kim
Journal:  Biomed Opt Express       Date:  2016-08-01       Impact factor: 3.732

Review 3.  Novel methods for mapping the cavernous nerves during radical prostatectomy.

Authors:  Nathaniel M Fried; Arthur L Burnett
Journal:  Nat Rev Urol       Date:  2015-08       Impact factor: 14.432

4.  PSMA expression by microvasculature of thyroid tumors - Potential implications for PSMA theranostics.

Authors:  Andrey Bychkov; Usanee Vutrapongwatana; Supatporn Tepmongkol; Somboon Keelawat
Journal:  Sci Rep       Date:  2017-07-12       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.